Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Recruiting now · Phase 3

Conditions studied: Von Willebrand Disease (VWD)

In brief

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Key facts

Study ID: NCT07115004
Run by: Vega Therapeutics, Inc
People needed: 60
Starts: 2025-10-15
Expected to finish: 2028-10-01
Last updated by the study team: 2026-04-03

Who can join

Age: 12 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Science 37, Inc. (Virtual Clinical MetaSite) — Morrisville, North Carolina, United States (enrolling)
Hemophilia Center of Western PA — Pittsburgh, Pennsylvania, United States (enrolling)
UT Southwestern Children's Hospital — Dallas, Texas, United States (enrolling)
Washington Center for Bleeding Disorders — Seattle, Washington, United States (enrolling)
K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი) — Tbilisi, Georgia (enrolling)
Frankfurt University Hospital (Universitätsmedizin Frankfurt) — Frankfurt, Germany (enrolling)
Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist — Johannesburg, South Africa (enrolling)
Arkansas Children's Hospital — Little Rock, Arkansas, United States (enrolling)
Luskin Orthopaedic Institute For Children — Los Angeles, California, United States (enrolling)
UC Davis Medical Center — Sacramento, California, United States (enrolling)
University of California San Francisco — San Francisco, California, United States (enrolling)
Emory University Hospital — Atlanta, Georgia, United States (enrolling)
Children's Healthcare of Atlanta — Atlanta, Georgia, United States (enrolling)
University of Minnesota — Minneapolis, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.